With cash rapidly running out, the UK's Midatech Pharma PLC hopes to have secured its future by merging with Bioasis Technologies, Inc. to create "a multi-asset rare and orphan disease company" that will be renamed Biodexa Pharmaceuticals.
Midatech, which trades on the US NASDAQ, is buying Toronto Stock Exchange-listed Bioasis for C$7.4m ($5.4m) in shares and announced...
Welcome to Scrip
Create an account to read this article
Already a subscriber?